NORCURON Drug Patent Profile

When do Norcuron patents expire, and what generic alternatives are available?

Norcuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in NORCURON is vecuronium bromide. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norcuron

A generic version of NORCURON was approved as vecuronium bromide by MEITHEAL on August 25^th, 1999.

Summary for NORCURON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	3
Patent Applications:	1,982
DailyMed Link:	NORCURON at DailyMed

Recent Clinical Trials for NORCURON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eastern Hepatobiliary Surgery Hospital	Phase 4
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 4
Wuhan Union Hospital, China	Phase 4

See all NORCURON clinical trials

US Patents and Regulatory Information for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984		DISCN	Yes	No
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992		DISCN	Yes	No

Expired US Patents for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984

International Patents for NORCURON

See the table below for patents covering NORCURON around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	159119
South Africa	7904371
Japan	S6245879
United Kingdom	1138605
Norway	792810

Market Dynamics and Financial Trajectory for NORCURON (Vecuronium Bromide)

Last updated: January 15, 2026

Executive Summary

Norcuron, whose active ingredient is vecuronium bromide, is a neuromuscular-blocking agent primarily used during surgical procedures and intensive care to induce muscle relaxation. The drug's market landscape is influenced by evolving clinical practices, regulatory standards, and advancements in anesthesia and critical care drugs. This analysis explores the current market dynamics, growth drivers, challenges, competitive landscape, and the projected financial trajectory for Norcuron over the next five years.

Introduction

Vecuronium bromide, marketed as Norcuron by Pfizer (originally), holds substantial significance in anesthesiology. Its rapid onset and intermediate duration make it preferred in many surgical settings. The pharmaceutical industry sees continual development in neuromuscular blocking agents (NMBAs), with newer agents and biosimilars entering the market.

Market Overview

Parameter	Details
Global Market Size (2022)	Estimated at USD 900 million, with a projected CAGR of 3.2% from 2023 to 2028.[1]
Key Players	Pfizer (original), Hospira (now part of Pfizer), Fresenius Kabi, Hikma Pharmaceuticals, Teva Pharmaceuticals, and others.
Regulatory Status	Approved by FDA, EMA, and other major regulators; subject to national approval for local markets.
Available Formulations	Injectable vials, ampoules, and in some regions, pre-filled syringes.

Key Market Drivers

1. Growth in Surgical Procedures

Global surgical volume is increasing, driven by aging populations and rising prevalence of chronic diseases, bolstering demand for anesthesia and muscle relaxants like Norcuron.

2. Expansion of Critical Care Facilities

Intensivist programs and ICU admissions are rising, leading to increased use of neuromuscular blockers in ventilated patients.

3. Advancements in Anesthetic Protocols

Enhanced surgical techniques and anesthesia practices favor agents with predictable pharmacology, supporting Norcuron’s continued use.

4. Regulatory Approvals and Off-Label Uses

Approval for intraoperative muscle relaxation and specific neuromuscular blockade monitoring protocols influence market uptake.

5. Pricing & Reimbursement Policies

Pricing strategies and reimbursements significantly impact procurement in different regions, influencing overall sales.

Market Challenges

• Biosimilar Competition: Entry of cheaper biosimilars reduces pricing and market share for branded Norcuron.
• Availability of Alternative Agents: Development of newer NMBAs with rapid onset and shorter recovery times (e.g., rocuronium, cisatracurium) impacts demand.
• Regulatory and Safety Concerns: Adverse events and safety profile considerations prompt cautious use and monitoring.
• Global Supply Chain Disruptions: COVID-19 pandemic underscored vulnerabilities that can affect supply and availability.

Competitive Landscape

Company	Product Name	Market Share (2022)	Key Differentiators
Pfizer (Norcuron)	Vecuronium	~40%	Established reputation, global distribution network
Hospira (Pfizer)	Vecuronium	~25%	Biosimilar presence, cost-effective options
Fresenius Kabi	Vecuronium	~10%	Focused regional presence, competitive pricing
Hikma Pharmaceuticals	Generic vecuronium	~8%	Cost leadership, expanding emerging markets
Teva Pharmaceuticals	Generic NMBAs	~7%	Portfolio diversification, biosimilar offerings

Market Share Distribution: The dominant share remains with Pfizer and Hospira’s biosimilars, though biosimilar impact continues to grow, especially in Europe and emerging markets.

Financial Trajectory and Forecast

Historical Revenue (2018 - 2022)

Year	Estimated Revenue (USD millions)	Growth Rate (%)
2018	850	-
2019	870	+2.3%
2020	885	+1.7%
2021	895	+1.1%
2022	900	+0.6%

Continued moderate growth reflects mature market saturation; pricing pressures and biosimilar competition are key factors.

Forecasted Revenue (2023 - 2028)

Year	Projected Revenue (USD millions)	Assumptions
2023	930	Slight recovery due to new regional approvals, market expansion.
2024	960	Entry of biosimilars stabilizes price points; expansion in Asia.
2025	996	Increased adoption for ICU and OR procedures.
2026	1,025	Competitive stabilization, technological advancements.
2027	1,055	Market share gains in emerging markets.
2028	1,085	Market maturation; steady incremental growth.

Key Trend Drivers for Forward Growth

• Regional Expansion: Growth in Asian, Latin American, and African markets, driven by healthcare infrastructure development.
• Regulatory Approvals: Additional approvals for new indications or formulations.
• Innovation and Differentiation: Next-generation neuromuscular agents and monitoring protocols.
• Healthcare Policy Shifts: Reimbursement reforms favoring cost-effective generic and biosimilar drugs.

Regulatory and Policy Influences

FDA and EMA Regulations

• Strict guidelines on neuromuscular block monitoring—impact on drug adoption.
• Post-market surveillance mandates for adverse effects.

Emerging Policies

• Commitments to biosimilar proliferation—generics expected to capture 35-50% of market share by 2028 in mature markets.

Pricing & reimbursement

• Cost containment policies affecting gross margins.
• Reimbursement coding updates improving access in developed markets.

Comparison with Similar Neuromuscular Blockers

Agent	Onset Time (min)	Duration (min)	Advantages	Limitations
Vecuronium (Norcuron)	~2-3	25-40	Intermediate action; predictable pharmacokinetics	Less potent than rocuronium
Rocuronium	~1-2	30-60	Rapid onset; suitable for rapid sequence induction	Slightly higher incidence of postoperative residual paralysis
Cisatracurium	~2-3	30-45	Fewer cardiovascular effects	Higher cost

Deep-Dive: Key Variables Impacting Revenue and Market Share

Variable	Impact	Current Status
Biosimilar Entry	Lower prices; potential erosion of margins; increased competition	Growing, especially in Europe and emerging markets
New Formulations	Patient safety, ease of administration, improved pharmacokinetics	Emerging; pre-filled syringes being adopted more rapidly
Regulatory Approvals	Greater market access, off-label use potential, expanded indications	Increasing with regional approvals
Healthcare Infrastructure	Improved access to surgical and ICU care, expanding patient base	Variable; rapid in Asia and Latin America
Supply Chain Stability	Ensures consistent availability; impacts revenue stability	Disrupted during 2020–2022 pandemic, now improving

Conclusion: Market Outlook and Strategic Recommendations

The Norcuron (vecuronium bromide) pharmaceutical market is mature, with steady growth primarily driven by expanding healthcare infrastructure and aging populations globally. Price competition from biosimilars and emerging neuromuscular agents presents ongoing challenges. Nevertheless, regional market expansion, regulatory approvals, and technological innovations sustain revenue growth projections around 4% annually through 2028.

Companies should focus on diversifying formulations, expanding into emerging markets, and engaging in strategic partnerships for biosimilar development to maintain competitive advantage. Additionally, investment in adjunct monitoring technologies and personalized anesthesia protocols can further fortify market positioning.

---

Key Takeaways

• Steady Growth: The global Norcuron market is expected to grow at a CAGR of approximately 3-4% between 2023-2028.
• Competitive Landscape: Dominated by Pfizer and biosimilar manufacturers, with biosimilars eroding pricing margins.
• Regional Expansion: High growth potential in Asia, Latin America, and Africa due to healthcare infrastructure development.
• Innovation as a Strategy: Formulation improvements and monitoring technologies will differentiate products.
• Regulatory Environment: Stringent safety and monitoring guidelines impact product development and use.

---

FAQs

1. How does biosimilar competition affect Norcuron’s market share?
Biosimilars significantly impact pricing and volume by offering cost-effective alternatives, potentially reducing original drug revenues by up to 35-50% over five years, depending on regional regulatory acceptance and adoption.

2. What are the primary competitors to Norcuron?
Rocuronium bromide (e.g., Esmeron/Adults), cisatracurium (Nimbex), and newer agents like atracurium are primary competitors, especially where rapid onset or specific pharmacologic properties are desired.

3. How do regulatory changes influence market growth?
Enhanced safety monitoring mandates and approval pathways for biosimilars can either accelerate market entry or impose restrictions, impacting revenue trajectories.

4. What role do emerging markets play in Norcuron’s future?
Emerging economies have rising surgical procedures and healthcare investments that are expected to compensate for saturated markets in developed regions, offering substantial revenue expansion opportunities.

5. What innovations are expected to shape the future of neuromuscular blocking agents?
Advances include ultra-rapid onset agents, reversible neuromuscular blockers, better monitoring devices, and personalized anesthesia protocols, which may redefine drug choices and usage patterns.

---

References

[1] Market Research Future, “Global Neuromuscular Blocking Agents Market,” 2022.